首页> 外国专利> Lactococcus lactis Th1- Th17- Th2- Composition for Preventing Improving or Treating of Th1-mediated Immune Disease Th17-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Lactococcus lactis as an Active Ingredients

Lactococcus lactis Th1- Th17- Th2- Composition for Preventing Improving or Treating of Th1-mediated Immune Disease Th17-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Lactococcus lactis as an Active Ingredients

机译：乳酸乳球菌Th1-Th17-Th2-预防或改善Th1介导的免疫病的组合物以乳酸乳球菌的提取物为有效成分的Th17介导的免疫病或Th2介导的免疫病

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to the use of lactococcus lactis (Lactococcus lactisMediated immune disease, Th17-mediated immune disease or Th2-mediated immune disease. Lactococcus lactis of the present invention reduces the production of immunoglobulin E (IgE) and reduces Th1-associated cytokine, Th17-related cytokine and Th2-associated cytokine production upon immunosuppressive action, An anti-allergic or anti-inflammatory composition that effectively controls disease, Th17-mediated immune disease or Th2-mediated immune disease.;

机译：本发明涉及乳酸乳球菌（乳酸乳球菌介导的免疫疾病，Th17介导的免疫疾病或Th2介导的免疫疾病的用途。本发明的乳酸乳球菌减少了免疫球蛋白E（IgE）的产生。）并减少免疫抑制作用下与Th1相关的细胞因子，Th17相关的细胞因子和Th2相关的细胞因子的产生;一种有效控制疾病，Th17介导的免疫性疾病或Th2介导的免疫性疾病的抗过敏或抗炎组合物。 展开▼

著录项

公开/公告号KR101724126B1

专利类型

公开/公告日2017-04-10

原文格式PDF

申请/专利权人 한국식품연구원;
展开▼

申请/专利号KR20150114937

发明设计人 시혜정;손동화;신희순;최대운;임성일;도정룡;엄지은;이소영;
展开▼

申请日2015-08-13

分类号A61K35/744;A23K1/00;A23L1/30;A61K8/99;

国家 KR

入库时间 2022-08-21 13:25:45

相似文献

专利

外文文献

中文文献

1. CQMU151在制备治疗Th17细胞介导自身免疫病药物中的应用 [P] . 中国专利： CN111658651B . 2021.08.03

2. CQMU152在制备治疗Th17细胞介导自身免疫病药物中的应用 [P] . 中国专利： CN111686100B . 2021.08.17

3. Lactococcus lactis Th1- Th17- Th2- Composition for Preventing Improving or Treating of Th1-mediated Immune Disease Th17-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Lactococcus lactis as an Active Ingredients [P] . 韩国专利： KR20170020679A . 2017-02-23

机译：乳酸乳球菌Th1-Th17-Th2-预防或改善Th1介导的免疫病的组合物以乳酸乳球菌的提取物为有效成分的Th17介导的免疫病或Th2介导的免疫病

4. Th1- Th17- Th2- Composition for Preventing Improving or Treating of Th1-mediated Immune Disease Th17-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients [P] . 韩国专利： KR20170020204A . 2017-02-22

机译：用于预防或改善Th1介导的免疫病的Th1-Th17-Th2-组合物包含来自乳杆菌的提取物作为有效成分的Th17介导的免疫病或Th2介导的免疫病

5. Th1- Th17- Th2- Composition for Preventing Improving or Treating of Th1-mediated Immune Disease Th17-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients [P] . 韩国专利： KR101761506B1 . 2017-07-25

机译：用于预防或改善Th1介导的免疫病的Th1-Th17-Th2-组合物包含来自乳杆菌的提取物作为有效成分的Th17介导的免疫病或Th2介导的免疫病

1. Immune Regulatory Cell Biology and Clinical Applications to Prevent or Treat Acute Graft-Versus-Host Disease [J] . Bruce R.Blazar 工程（英文） . 2019,第001期

2. Immune Regulatory Cell Biology and Clinical Applications to Prevent or Treat Acute Graft-Versus-Host Disease [J] . Bruce R. Blazar 工程（英文） . 2019,第001期

3. 14-3-3 gamma and zeta protein expression in active microglia Immune response mechanisms of Parkinson's disease [J] . Jing He, Shenggang Sun, Xiaowu Chen 中国神经再生研究（英文版） . 2008,第003期

4. Effects of dietary Lactobacillus rhamnosus JCM1136 and Lactococcus lactis subsp lactis JCM5805 on the growth, intestinal microbiota, morphology, immune response and disease resistance of juvenile Nile tilapia, Oreochromis niloticus [J] . Xia Yun, Lu Maixin, Chen Gang, Fish & Shellfish Immunology . 2018,第期

5. Effects of i >Lactococcus lactis/i>Lactococcus lactis MG1363 producing fusion proteins of bovine lactoferricin–lactoferrampin on growth, intestinal morphology and immune function in weaned piglet [J] . Song L., Qiao X., Zhao D., Journal of applied microbiology . 2019,第3期

6. Analysis of Immune Responses in Mice Orally Immunized with Recombinant pMG36e-SP-TSOL18/Lactococcus lactis and pMG36e-TSOL18/Lactococcus lactis Vaccines of Taenia solium [J] . Bi Ying Zhou, Jun Chao Sun, Xiang Li, Clinical & developmental immunology. . 2018,第1期

7. Preliminary Results: Lactococcus lactis lactis and Streptococcus uberis Invasion and Immune Activation of a Bovine Mammary [C] . Epithelial Cell Line Annual^Meeting of the National^Mastitis^Council . 2016

8. Effective combination of syngeneic HCT with CRCL vaccination to treat BCR-ABL+ leukemia, and, CD4+CD25+FOXP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. [D] . Chen, Xinchun. 2006

9. Analysis of Immune Responses in Mice Orally Immunized with Recombinant pMG36e-SP-TSOL18/Lactococcus lactis and pMG36e-TSOL18/Lactococcus lactis Vaccines of Taenia solium [O] . Bi Ying Zhou, Jun Chao Sun, Xiang Li, 2018

10. Oral administration of Lactococcus lactis subsp. lactis JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection. [O] . Kenta Jounai, Tetsu Sugimura, Konomi Ohshio, 2015

1. NisP　Is　Related　to　Nisin　Precursor　Processing　and　Possibly　to　Immunity　in　Lactococcus　Lactis [J] . 叶嗣颖 . 华中科技大学学报：医学英德文版 . 1995,第004期

2. Graves’ Disease as a Late Manifestation of Immune Reconstitution Syndrome after Highly Active Antiretroviral Therapy in an HIV-1 Infected Patient [J] . Evelin Mingote ,Agustina Urrutia ,Alejandra Viteri . 艾滋病（英文） . 2013,第3期

3. Fas/FasL介导的T细胞凋亡与自身免疫病研究进展 [C] . 王海隆 ,张显彬 ,冯兴华 . 第十一届全国中医风湿病学术研讨会 . 2006

4. E3泛素连接酶CRL4DCAF2在调节T细胞增殖及T细胞介导的自身免疫病中的功能及机制研究 [A] . 王斐 . 2020

获取专利

意见反馈

回到顶部

回到首页

关于掌桥

资源导航

新手指南

常见问题

网站地图

版权声明

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信

服务号